The FDA Wednesday afternoon granted accelerated approval with breakneck speed – more than five months ahead of its May 19, 2015, PDUFA date – to Amgen Inc.'s blinatumomab to treat patients with relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, or B-cell ALL, a rare form of ALL.